Press Release

View printer-friendly version
« Back
Voyager Therapeutics to Present at Investor Conferences in November

CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences:

  • Stifel 2017 Healthcare Conference, New York City
    Date: Wednesday, November 15, 2017
    Time: 2:00 p.m. EST
    Panel Members:  Jane Henderson, chief financial officer and senior vice president of corporate development and Bernard Ravina, M.D., M.S., chief medical officer
     
  • Piper Jaffray Healthcare Conference, New York City
    Date: Tuesday, November 28, 2017
    Time: 9:00 a.m. EST
    Panel Members: Jane Henderson, chief financial officer and senior vice president of corporate development and Bernard Ravina, M.D., M.S., chief medical officer

  • Evercore ISI Biopharma Catalyst/Deep Dive Conference, Boston, MA
    Date: Wednesday, November 29, 2017
    Time: 3:30 p.m. EST
    Panel Members: Steven Paul, M.D., president and chief executive officer and Jane Henderson, chief financial officer and senior vice president of corporate development

Live-streaming webcasts of these presentations can be accessed through the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com.  The webcast will be archived for 30 days after the live event concludes.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School.  Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts.  For more information, please visit www.voyagertherapeutics.com

Investor Relations:
Matt Osborne
Vice President of Investor Relations & Corporate Communications
857-259-5353
mosborne@vygr.com 

Media:
Katie Engleman
Pure Communications, Inc.
910-509-3977
Katie@purecommunicationsinc.com 

Voyager Therapeutics, Inc.